Edesa Biotech Inc expected to post a loss of 26 cents a share - Earnings Preview

Edesa Biotech

05/08/2025 12:23

Edesa Biotech Inc EDSA.OQ EDSA.O is expected to  show no change in quarterly revenue when it reports  results on August 7 (estimated) for the period ending June 30 2025

​LSEG's mean analyst estimate for Edesa Biotech Inc is for a loss of 26 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Edesa Biotech Inc is $9.00, about 74.8% above its last closing price of $2.27

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2025
-0.36
-0.29
-0.30
Missed
-1.7
Dec. 31 2025
-0.31
-0.31
-0.48
Missed
-54.8
Sep. 30 2024
-0.63
-0.54
-0.29
Beat
46.3​
Jun. 30 2024
-0.71
-0.58
-0.52
Beat
10.3
​​Mar. 31 2024
-0.62
-0.69
-0.58
Beat
16.3
Dec. 31 2023
-1.41
-1.21
-0.54
Beat
55.4​
Sep. 30 2023
-0.71
-0.71
-0.60
Beat
15.1
Jun. 30 2023
-1.10
-1.21
-0.70
Beat
42.3

This summary was machine generated August 5 at 11:23 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)